We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Ties that bind

28 September 2021 By Robert Cyran

The $186 bln drug giant may buy the $11 bln Acceleron. That would help Merck diversify by adding two possible blockbusters. But Acceleron already has a partner for both: Bristol Myers, which could yet lob in a bid. If Merck does prevail, the mix risks an adverse reaction.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)